Is structural remodeling of fibrillated atria the consequence of tissue hypoxia?

Circulation Journal

Volumn 74, Issue 9, 2010, Pages 1815-1821

  Ogi, Hiroshi ^a   Nakano, Yukiko ^a   Niida, Shumpei ^b   Dote, Keigo ^c   Hirai, Yukoh ^a   Suenari, Kazuyosi ^a   Tonouchi, Yukiji ^a   Oda, Noboru ^a   Makita, Yuko ^a   Ueda, Shigeyuki ^a   Kajihara, Kenta ^a   Imai, Katsuhiko ^a   Sueda, Taijro ^a   Chayama, Kazuaki ^a   Kihara, Yasuki ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

^c HIROSHIMA CITY ASA HOSPITAL   (Japan)

Author keywords

Atrial fibrillation; Hypoxia; Hypoxia induced transcription factor 1a (HIF 1a); Matrix metalloproteinase 9 (MMP 9); Vascular endothelial growth factor (VEGF)

Indexed keywords

GELATINASE B; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM; FEMALE; HEART ATRIUM; HEART ATRIUM FIBRILLATION; HUMAN; HUMAN TISSUE; HYPOXEMIA; IMMUNOFLUORESCENCE; MALE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; SINUS RHYTHM; TISSUE DISTRIBUTION; UPREGULATION; WESTERN BLOTTING;

AGED; ANOXIA; ATRIAL FIBRILLATION; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; MIDDLE AGED; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RNA, MESSENGER; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77956125635     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-09-0969     Document Type: Article

References (50)

1. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiological features of atrial fibrillation: The Framingham study. N Engl J Med 1982; 306: 1018-1022.
2. Lévy S, Breithardt G, Campbell RW, Camm AJ, Daubert JC, Allessie M, et al. Atrial fibrillation: Current knowledge and recommendations for management: Working Group on Arrhythmias of the European Society of Cardiology. Eur Heart J 1998; 19: 1294-1320.
3. Meiltz A, Zimmermann M, Urban P, Bloch A; Association of Cardiologists of the Canton of Geneva. Atrial fibrillation management by practice cardiologists: A prospective survey on the adherence to guidelines in the real world. Europace 2008; 10: 674-680.
4. Psaty BM, Manolio TA, Kuller LH, Kronmal RA, Cushman M, Fried LP, et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation 1997; 96: 2455-2461.
5. Allessie MA, Boyden PA, Camm AJ, Kléber AG, Lab MJ, Legato MJ, et al. Pathophysiology and prevention of atrial fibrillation. Circulation 2001; 103: 769-777.
6. Ausma J, van der Velden HM, Lenders MH, van Ankeren EP, Jongsma HJ, Ramaekers FC, et al. Reverse structural and gapjunctional remodeling after prolonged atrial fibrillation in the goat. Circulation 2003; 107: 2051-2058.
7. Allessie M, Ausma J, Schotten U. Electrical contractile and structural remodeling during atrial fibrillation. Cardiovasc Res 2002; 54: 230-246.
8. Ausma J, Litjens N, Lenders MH, Duimel H, Mast F, Wouters L, et al. Time course of atrial fibrillation-induced cellular structural remodeling in atria of the goat. J Mol Cell Cardiol 2001; 33: 2083-2094.
9. Polontchouk L, Haefliger JA, Ebelt B, Schaefer T, Stuhlmann D, Mehlhorn U, et al. Effects of chronic atrial fibrillation on gap junction distribution in human and rat atria. J Am Coll Cardiol 2001; 38: 883-891.
10. van der Velden HM, Ausma J, Rook MB, Hellemons AJ, van Veen TA, Allessie MA, et al. Gap junctional remodeling in relation to stabilization of atrial fibrillation in the goat. Cardiovasc Res 2000; 46: 476-486.
11. Arndt M, Lendeckel U, Röcken C, Nepple K, Wolke C, Spiess A, et al. Altered expression of ADAMs (A Disintegrin And Metalloproteinase) in fibrillating human atria. Circulation 2002; 105: 720-725.
12. Li YY, Feldman AM, Sun Y, McTiernan CF. Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation 1998; 98: 1728-1734.
13. Thomas CV, Coker ML, Zellner JL, Handy JR, Crumbley AJ 3rd, Spinale FG. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation 1998; 97: 1708-1715.
14. Creemers EE, Cleutjens JP, Smits JF, Daemen MJ. Matrix metalloproteinase inhibition after myocardial infarction: A new approach to prevent heart failure? Circ Res 2001; 89: 201-210.
15. Spinale FG. Matrix metalloproteinases: Regulation and dysregulation in the failing heart. Circ Res 2002; 90: 520-530.
16. Lin X, Jo H, Ishii TM, Fujita M, Fu M, Tambara K, et al. Controlled release of matrix metalloproteinase-1 plasmid DNA prevents left ventricular remodeling in chronic myocardial infarction of rats. Circ J 2009; 73: 2315-2321.
17. Spinale FG, Coker ML, Heung LJ, Bond BR, Gunasinghe HR, Etoh T, et al. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 2000; 102: 1944-1949.
18. Ducharme A, Frantz S, Aikawa M, Rabkin E, Lindsey M, Rohde LE, et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest 2000; 106: 55-62.
19. Spinale FG, Coker ML, Bond BR, Zellner JL. Myocardial matrix degradation and metalloproteinase activation in the failing heart: A potential therapeutic target. Cardiovasc Res 2000; 46: 225-238.
20. Romanic AM, Harrison SM, Bao W, Burns-Kurtis CL, Pickering S, Gu J, et al. Myocardial protection from ischemia/reperfusion injury by targeted deletion of matrix metalloproteinase-9. Cardiovasc Res 2002; 54: 549-558.
21. Isobe K, Kuba K, Maejima Y, Suzuki J, Kubota S, Isobe M. Inhibition of endostatin/collagen XVIII deteriorates left ventricular remodeling and heart failure in rat myocardial infarction model. Circ J 2010; 74: 109-119.
22. Nakano Y, Niida S, Dote K, Takenaka S, Hirao H, Miura F, et al. Matrix metalloproteinase-9 contributes to human atrial remodeling during atrial fibrillation. J Am Coll Cardiol 2004; 43: 818-825.
23. Nozawa H, Chiu C, Hanahan D. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci USA 2006; 103: 12493-12498.
24. Lee S, Jilani SM, Nikolova GV, Carpizo D, Iruela-Arispe ML. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol 2005; 169: 681-691.
25. Wang H, Keiser JA. Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells: Role of flt-1. Circ Res 1998; 83: 832-840.
26. Owen JL, Iragavarapu-Charyulu V, Gunja-Smith Z, Herbert LM, Grosso JF, Lopez DM. Up-regulation of matrix metalloproteinase-9 in T lymphocytes of mammary tumor bearers: Role of vascular endothelial growth factor. J Immunol 2003; 171: 4340-4351.
27. Hollborn M, Stathopoulos C, Steffen A, Wiedemann P, Kohen L, Bringmann A. Positive feedback regulation between MMP-9 and VEGF in human RPE cells. Invest Ophthalmol Vis Sci 2007; 48: 4360-4367.
28. Lee SH, Wolf PL, Escudero R, Deutsch R, Jamieson SW, Thistlethwaite PA. Early expression of angiogenesis factors in acute myocardial ischemia and infarction. N Engl J Med 2000; 342: 626-633.
29. Oka T, Komuro I. Molecular mechanisms underlying the transition of cardiac hypertrophy to heart failure. Circ J 2008; 72(Suppl A): A-13-A-16.
30. Huang LE, Gu J, Schau M, Bunn HF. Regulation of hypoxiainducible factor 1αis mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 1998; 95: 7987-7992.
31. Semenza GL. HIF-1: Mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol 2000; 88: 1474-1480.
32. Jones A, Fujiyama C, Blanche C, Moore JW, Fuggle S, Cranston D, et al. Relation of vascular endothelial growth factor production to expression and regulation of hypoxia-inducible factor-1 alpha and hypoxia-inducible factor-2 alpha in human bladder tumors and cell lines. Clin Cancer Res 2001; 7: 1263-1272.
33. Lai LP, Su MJ, Lin JL, Lin FY, Tsai CH, Chen YS, et al. Downregulation of L-type calcium channel and sarcoplasmic reticular Ca(2+)-ATPase mRNA in human atrial fibrillation without significant change in the mRNA of ryanodine receptor, calsequestrin and phospholamban: An insight into the mechanism of atrial electrical remodeling. J Am Coll Cardiol 1999; 33: 1231-1237.
34. Brundel BJ, Van Gelder IC, Henning RH, Tieleman RG, Tuinenburg AE, Wietses M, et al. Ion channel remodeling is related to intraoperative atrial effective refractory periods in patients with paroxysmal and persistent atrial fibrillation. Circulation 2001; 103: 684-690.
35. Brundel BJ, Henning RH, Kampinga HH, Van Gelder IC, Crijns HJ. Molecular mechanisms of remodeling in human atrial fibrillation. Cardiovasc Res 2002; 54: 315-324.
36. Dobrev D, Graf E, Wettwer E, Himmel HM, Hála O, Doerfel C, et al. Molecular basis of downregulation of G-protein-coupled inward rectifying K(+) current (I(K,ACh)) in chronic human atrial fibrillation: Decrease in GIRK4 mRNA correlates with reduced I(K,ACh) and muscarinic receptor-mediated shortening of action potentials. Circulation 2001; 104: 2551-2557.
37. White CW, Kerber RE, Weiss HR, Marcus ML. The effects of atrial fibrillation on atrial pressure-volume and flow relationships. Circ Res 1982; 51: 205-215.
38. Thijssen VL, van der Velden HM, van Ankeren EP, Ausma J, Allessie MA, Borgers M, et al. Analysis of altered gene expression during sustained atrial fibrillation in the goat. Cardiovasc Res 2002; 54: 427-437.
39. Shinagawa K, Shi YF, Tardif JC, Leung TK, Nattel S. Dynamic nature of atrial fibrillation substrate during development and reversal of heart failure in dogs. Circulation 2002; 105: 2672-2678.
40. Gramley F, Lorenzen J, Jedamzik B, Gatter K, Koellensperger E, Munzel T, et al. Atrial fibrillation is associated with cardiac hypoxia. Cardiovasc Pathol 2010; 19: 102-111.
41. Kimura H, Weisz A, Kurashima Y, Hashimoto K, Ogura T, D'Acquisto F, et al. Hypoxia response element of the human vascular endothelial growth factor gene mediates transcriptional regulation by nitric oxide: Control of hypoxia-inducible factor-1 activity by nitric oxide. Blood 2000; 95: 189-197.
42. Jiang B, Dong H, Zhang Z, Wang W, Zhang Y, Xu X. Hypoxic response elements control expression of human vascular endothelial growth factor(165) genes transferred to ischemia myocardium in vivo and in vitro. J Gene Med 2007; 9: 788-796.
43. Chung NA, Belgore F, Li-Saw-Hee FL, Conway DS, Blann AD, Lip GY. Is the hypercoagulable state in atrial fibrillation mediated by vascular endothelial growth factor? Stroke 2002; 33: 2187-2191.
44. Gerber HP, Condorelli F, Park J, Ferrara N. Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes: Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. J Biol Chem 1997; 272: 23659-23667.
45. Kim CH, Cho YS, Chun YS, Park JW, Kim MS. Early expression of myocardial HIF-1alpha in response to mechanical stresses: Regulation by stretch-activated channels and the phosphatidylinositol 3- kinase signaling pathway. Circ Res 2002; 90: E25-E33.
46. Everett TH 4th, Olgin JE. Atrial fibrosis and the mechanisms of atrial fibrillation. Heart Rhythm 2007; 4(Suppl): S24-S27.
47. Zheng W, Seftor EA, Meininger CJ, Hendrix MJ, Tomanek RJ. Mechanisms of coronary angiogenesis in response to stretch: Role of VEGF and TGF-beta. Am J Physiol Heart Circ Physiol 2001; 280: H909-H917.
48. Belotti D, Calcagno C, Garofalo A, Caronia D, Riccardi E, Giavazzi R, et al. Vascular endothelial growth factor stimulates organ-specific host matrix metalloproteinase-9 expression and ovarian cancer invasion. Mol Cancer Res 2008; 6: 525-534.
49. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000; 2: 737-744.
50. Hiratsuka S, Nakamura K, Iwai S, Murakami M, Itoh T, Kijima H, et al. MMP9 induction by vascular endothelial growth factor receptor- 1 is involved in lung-specific metastasis. Cancer Cell 2002; 2: 289-300.